Australia, April 18 -- Argenx B.V., owns the trademark (2558014) for 'ARGENX' till March 10, 2035.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceuticals and medical preparations for therapeutic purposes in the field of immunology and autoimmune diseases; pharmaceutical preparations for the prevention or treatment of autoimmune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, and transplantation-related diseases and disorders, cancer and diseases of the immune system; compositions of antibodies or fragments of antibodies or derivatives of antibodies with therapeutic properties; antibodies or fragments of antibodies or derivatives of antibodies for the prevention or treatment of autoimmune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, transplantation-related diseases and disorders, cancer and diseases of the immune system.], 35 [Wholesale and retail services for therapeutic pharmaceutical preparations in the field of immunology and auto-immune diseases and antibodies or fragments or derivatives of antibodies with therapeutic properties; administrative services in relation to patient information in the field of immunology, diseases of the immune system and antibody therapeutics; business administration of patient reimbursement programs.], 42 [Research and development in the field of immunology, antibody engineering and autoimmune diseases for therapeutic purposes; therapeutic drug research and development in the field of immunology, antibody technology and autoimmune diseases; scientific and technological services and research relating to immunity, autoimmune diseases and antibody engineering for therapeutic purposes; providing medical and scientific research information in the field of therapeutic pharmaceuticals, clinical trials, research and development.] and 44 [Providing information to patients in the field of auto-immune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, and transplantation-related diseases and disorders, cancer and diseases of the immune system and the treatment thereof; consultancy and information services relating to therapeutic biopharmaceutical products; provision of information on therapeutic pharmaceutical, medical, and healthcare products to customers or patients through an online computer network.]
Type of Mark: Word
Date of Acceptance: Feb. 10
Registration Advertised: April 17
For further details contact Spruson & Ferguson and Boult Wade Tennant LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2558014.
Disclaimer: Curated by HT Syndication.
